Table 1.
Demographic and clinical characteristics of CP-TB patients, NCP-TB patients and healthy individuals in training and validation sets.
Fig 1.
Flow chart of the experimental design.
Fig 2.
MiRNA expression in plasma derived from CP-TB, NCP-TB patients and healthy controls (H).
Table 2.
Relative miRNA expression level to let-7 in plasma samples derived from TB patients and control subjects in the training set.
Fig 3.
Detection of TB using 3 plasma miRNAs as a biomarker.
A hydrolysis probe–based qRT-PCR assay was used to measure the relative levels of the 3 miRNAs in 64 CP-TB patients, 64 NCP-TB patients and 64 healthy controls (in both the training and validation set). Each point represents the mean of the results for triplicate. The asterisks indicate significant differences compared to healthy controls. * P<0.05; ** P<0.01; *** P<0.001. (A) miR-769-5p, (B) miR-320a and (C) miR-22-3p.
Table 3.
Relative miRNA expression level to let-7 in plasma samples derived from TB patients and control subjects in the validation set.
Fig 4.
ROC curves to compare the ability of miRNA to distinguish TB patients from the healthy controls.
(A-D) miR-769-5p, miR-320a, miR-22-3p and the three-miRNA panel for discriminating between NCP-TB patients and healthy controls; (E-H) miR-769-5p, miR-320a, miR-22-3p and the three-miRNA panel for discriminating between CP-TB patients and healthy controls; (I-L) miR-769-5p, miR-320a, miR-22-3p and the three-miRNA panel for discriminating between TB patients and healthy controls.
Table 4.
Risk score analysis of TB patients and healthy controls.
Fig 5.
Downregulation of miR-320a in plasma from drug-resistant TB patients compared with drug-susceptible TB patients.
(A) Relative concentration of miR-320a in plasma derived from drug-resistant and drug-susceptible TB patients. (B) ROC curves to comparing the ability of miR-320a to distinguish between drug-resistant TB and drug-susceptible TB.
Table 5.
Demographic and clinical characteristics of drug-resistant TB patients.
Table 6.
Relative miRNA expression levels to let-7 in plasma samples derived from drug-resistant and pan-susceptible TB patients.